Based on the discovery of the critical regulatory role of the RSK2-IκBα-NF-κB signalling axis44, this study proposes that a leading RSK2 inhibitor holds significant potential for managing pancreatic cancer metastasis (Figures 7 and 8). Here, NFKB1 is linked to familial pancreatic carcinoma.